| Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia M Gbadamosi, S Meshinchi, JK Lamba Future Oncology 14 (30), 3199-3213, 2018 | 29 | 2018 |
| CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33 … I Papageorgiou, MR Loken, LE Brodersen, M Gbadamosi, GL Uy, ... Leukemia & lymphoma, 2019 | 14 | 2019 |
| Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML NHK Nguyen, R Rafiee, A Tagmount, A Sobh, A Loguinov, ... Blood Advances 7 (9), 1769-1783, 2023 | 9 | 2023 |
| A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials MO Gbadamosi, VM Shastri, AH Elsayed, R Ries, O Olabige, ... Leukemia 36 (8), 2022-2031, 2022 | 8 | 2022 |
| Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms MO Gbadamosi, VM Shastri, T Hylkema, I Papageorgiou, L Pardo, ... Future Oncology 17 (03), 263-277, 2021 | 8 | 2021 |
| The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-directed Gemtuzumab Ozogamicin MO Gbadamosi, VM Shastri, S Meshinchi, JK Lamba Blood 138, 2247, 2021 | 2 | 2021 |
| DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's … VM Shastri, L Chauhan, M Gbadamosi, TA Alonzo, YC Wang, R Aplenc, ... Clinical Cancer Research, OF1-OF9, 2024 | | 2024 |
| Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group. VM Shastri, L Chauhan, M Gbadamosi, TA Alonzo, YC Wang, R Aplenc, ... Clinical Cancer Research: an Official Journal of the American Association …, 2024 | | 2024 |
| Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms VM Shastri, MO Gbadamosi, JK Lamba Blood 142, 5749, 2023 | | 2023 |
| Cd33 antibodies JK Lamba, MO Gbadamosi, V Shastri US Patent App. 18/026,195, 2023 | | 2023 |
| Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant VM Shastri, TA Hylkema, MO Gbadamosi, S Meshinchi, JK Lamba Blood 138, 1290, 2021 | | 2021 |
| Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms M Gbadamosi, TA Hylkema, S Meshinchi, JK Lamba Blood 134, 908, 2019 | | 2019 |
| Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin M Gbadamosi, AH Elsayed, RE Ries, S Meshinchi, JK Lamba Blood 134, 1401, 2019 | | 2019 |
Soheil MeshinchiFull Professor, Fred Hutchinson Cancer Research Center在 fredhutch.org 的电子邮件经过验证
